Update date
31 Dec 2025
Shareable Research Card
AUPH - Aurinia Pharmaceuticals Inc. Current Ratio
This metric view shows AUPH - Aurinia Pharmaceuticals Inc. current ratio history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: Q4 2025
- Latest reported value
- 5.25x
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: Q4 2025.
- Latest reported value on this page: 5.25x.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Current Ratio
Latest reported current ratio: 5.25x. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 26 Feb 2026.
Benchmark Context
How Current Ratio compares with peers
Aurinia Pharmaceuticals Inc. is outside the visible top 120 companies for current ratio in the current sample.
Compared with
Compared with 120 companies reporting current ratio in x. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 0.1x the current sample midpoint. Current Ratio is up about 15% versus the comparable prior period.
- Visible rows currently span reported period ends from 30 Jun 2017 to 28 Feb 2026.
- Nearby companies in this sample: Invesco CurrencyShares Australian Dollar Trust and Invesco CurrencyShares British Pound Sterling Trust.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Financial Metric Page
Aurinia Pharmaceuticals Inc.: Current Ratio
Latest period: Q4 2025. Period end: 31 Dec 2025. Units: x. Frequency: quarterly.
The current ratio is a liquidity ratio that measures a company's ability to cover its short-term obligations with its current assets.
Metric Snapshot
- Latest value
- 5.25x
- Coverage range
- 31 Dec 2019 - 31 Dec 2025
- Fact rows
- 22
What This Metric Tells You
- Shows the reported level of current ratio over 31 Dec 2019 - 31 Dec 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 22 SEC fact rows for this metric and issuer.
How To Read This Chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use quarterly sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC Source
Source: SEC Company Facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
Compare This Metric Across Companies
Compare latest available Current Ratio levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
| Rank | Company | Latest value | Reported period | Next step |
|---|---|---|---|---|
| 1 | Invesco CurrencyShares Australian Dollar Trust (fxa) | 2,984.55x | Instant - 31 Mar 2019 | Open Invesco CurrencyShares Australian Dollar Trust Current Ratio |
| 2 | Invesco CurrencyShares British Pound Sterling Trust (fxb) | 2,934.36x | Instant - 31 Mar 2019 | Open Invesco CurrencyShares British Pound Sterling Trust Current Ratio |
| 3 | Invesco CurrencyShares Japanese Yen Trust (fxy) | 2,057.85x | Instant - 31 Mar 2019 | Open Invesco CurrencyShares Japanese Yen Trust Current Ratio |
| 4 | Invesco CurrencyShares Swiss Franc Trust (fxf) | 1,012.45x | Instant - 31 Mar 2019 | Open Invesco CurrencyShares Swiss Franc Trust Current Ratio |
| 5 | STARRY SEA ACQUISITION CORP (ssea) | 690.21x | Instant - 31 Dec 2025 | Open STARRY SEA ACQUISITION CORP Current Ratio |
| 6 | Anbio Biotechnology (nnnn) | 344.31x | Instant - 31 Dec 2025 | Open Anbio Biotechnology Current Ratio |
Metric Details
- Metric
- Current Ratio (CurrentRatio)
- Taxonomy
- ratio
- Units tracked
- x
- Frequency coverage
- quarterly
- History range
- 31 Dec 2019 - 31 Dec 2025
- Facts on this page
- 22
- Description
- The current ratio is a liquidity ratio that measures a company's ability to cover its short-term obligations with its current assets.
- Metric-level SEC endpoint
- Open SEC company concept
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Current Ratio, Quarterly (x)
Current Ratio, YoY Quarterly Change (%)
Aurinia Pharmaceuticals Inc. Quarterly Current Ratio (x)
| Period | Value | YoY Chg | Change % | Date |
|---|---|---|---|---|
| Q4 2025 | 5.25x | +0.68x | +15% | 31 Dec 2025 |
| Q3 2025 | 5.76x | +0.15x | +2.7% | 30 Sep 2025 |
| Q2 2025 | 5.23x | -0.1x | -1.9% | 30 Jun 2025 |
| Q1 2025 | 5.93x | +0.33x | +5.8% | 31 Mar 2025 |
| Q4 2024 | 4.57x | -0.94x | -17% | 31 Dec 2024 |
| Q3 2024 | 5.6x | -0.17x | -2.9% | 30 Sep 2024 |
| Q2 2024 | 5.33x | -1.42x | -21% | 30 Jun 2024 |
| Q1 2024 | 5.6x | -4.47x | -44% | 31 Mar 2024 |
| Q4 2023 | 5.5x | -4.09x | -43% | 31 Dec 2023 |
| Q3 2023 | 5.77x | -5.24x | -48% | 30 Sep 2023 |
| Q2 2023 | 6.75x | -6.34x | -48% | 30 Jun 2023 |
| Q1 2023 | 10.08x | -4.04x | -29% | 31 Mar 2023 |
| Q4 2022 | 9.6x | -3.03x | -24% | 31 Dec 2022 |
| Q3 2022 | 11.01x | +2.24x | +25% | 30 Sep 2022 |
| Q2 2022 | 13.09x | +1.16x | +9.7% | 30 Jun 2022 |
| Q1 2022 | 14.11x | -3.48x | -20% | 31 Mar 2022 |
| Q4 2021 | 12.63x | -0.48x | -3.7% | 31 Dec 2021 |
| Q3 2021 | 8.77x | 30 Sep 2021 | ||
| Q2 2021 | 11.93x | 30 Jun 2021 | ||
| Q1 2021 | 17.6x | 31 Mar 2021 | ||
| Q4 2020 | 13.11x | -14.79x | -53% | 31 Dec 2020 |
| Q4 2019 | 27.9x | 31 Dec 2019 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.